Iminostilbene voltage-gated sodium channel blocker
A first-generation iminostilbene anticonvulsant and mood stabilizer with potent CYP3A4 induction.
Abstract
Carbamazepine (5H-dibenzo[b,f]azepine-5-carboxamide; CAS 298-46-4; molecular formula C15H12N2O; molecular weight 236.27) is an iminostilbene anticonvulsant developed by Walter Schindler at Geigy in 1953 and approved by the FDA in 1968 under the trade name Tegretol. Mechanism: state-dependent voltage-gated sodium channel inhibition (similar to lamotrigine), producing reduced neuronal hyperexcitability in seizure foci. Active metabolite carbamazepine-10,11-epoxide retains anticonvulsant activity. Plasma half-life is 25 to 65 hours initially but auto-induces own metabolism, dropping to 12 to 17 hours at steady state. Strong CYP3A4 induction produces clinically significant interactions with hormonal contraception, immunosuppressants, anticoagulants, antiretrovirals, and many other drugs. Approved for partial-onset and generalized tonic-clonic seizures, trigeminal neuralgia, and bipolar I mania (in combination products). The principal safety concerns are aplastic anemia and agranulocytosis (rare but serious; HLA-B*1502 association predicts SJS/TEN risk in Asian populations and is screened pretreatment). Used as the reference iminostilbene voltage-gated sodium channel blocker.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.